Navigation Links
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
Date:10/17/2011

for the application of its recombinant human enzyme, rHuPH20, to three pre-defined biologic targets exclusive to Roche. In December 2008, Roche selected a fourth biologic target followed by selection of a fifth target in June 2009 and has the option to exclusively develop and commercialize rHuPH20 with an additional eight potential targets. In February 2011, Roche began a Phase 3 registration trial of subcutaneous (SC) MabThera (rituximab), an anticancer biologic, in patients with non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Pending the successful achievement of a series of clinical, regulatory, and sales events, Roche will pay Halozyme additional milestones as well as royalties on future product sales.  

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter, ViroPharma and Intrexon to apply Enhanze™ technology to therapeutic biologics including Herceptin®, MabThera®, immunoglobulin, Cinryze® and recombinant human alpha 1-antitrypsin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Safe Harbor Statement

In addition to hist
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Halozyme Therapeutics Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Fla. , Jan. 23, 2015  Today the U.S. ... Novartis, Bexsero® for the prevention of serogroup B ... Bexsero and Pfizer,s vaccine Trumenba®, which received FDA approval ... prevent this devastating disease. "I have ...
(Date:1/23/2015)... , Jan. 23, 2015 Research and Markets ... the "Urinary Catheters Market (Indwelling or Foley Catheters, ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... , At present, the global market for ...
(Date:1/23/2015)... Inc. (NASDAQ: NWBO )("NW Bio"), a U.S. biotechnology ... solid tumor cancers, announced today that CEO Linda Powers ... Immunotherapy Forum in Washington D.C. ... January 26 at 10:30 a.m. EST at the Grand Hyatt ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3
... 21, 2011 Henry Schein, Inc. (Nasdaq: HSIC ... to office-based dental, medical and veterinary practitioners, announced that it ... response to the tragic earthquake and tsunami that hit Northern ... rest of the world, we are deeply saddened by the ...
... DETROIT, March 20, 2011 Webahn, Inc. today announced ... for physicians, now includes instant messaging capability. Capzule (capzule.com) ... small practices as a software service. Physicians ... their iPhone or iPad of items that require immediate ...
Cached Medicine Technology:Henry Schein Establishes Matching Humanitarian Relief Fund in Response to Japan Earthquake and Tsunami 2Henry Schein Establishes Matching Humanitarian Relief Fund in Response to Japan Earthquake and Tsunami 3
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David Leadbetter ... to bestow a Juvent Sports Achievement award upon an ... The award commemorated and congratulated McKitrick for her record ... her first amateur tournament in 1979 and most recently ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... January 22, 2015 Yesterday, Senator ... (D-Concord) and Kristin Olsen (R-Modesto) were honored by ... in advancing biotechnology, biomedical science, medical device and ... each received the “2014 Life Sciences Champion” award ...
(Date:1/22/2015)... 2015 Payday lending practices in four ... cause financial distress to the states that permit them, ... University’s Center on Race and Wealth. , While they ... payday loans at the same time substantially depress economic ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... significantly contributed to the knowledge and treatment ... NEW YORK, Oct. 15 Five of ... presented to scientists of great,achievement by NARSAD, the ... an awards dinner here this Friday at the,Waldorf-Astoria ...
... bring new treatment options for patients, researchers say ... patients may one day find nicotine patches or ... researchers say. , Nicotine patches and the hot ... according to two studies presented at the American ...
... factor DMP1 as a pivotal tumor suppressor for both human ... Arf-p53 pathways. The research, published by Cell Press in the ... to development of new drug therapies for lung cancer. , ... the world, responsible for 1.3 million deaths each year. Non-small-cell ...
... Two clinical,research scientists this month joined Biomoda, Inc. ... NM, to assist with,commercialization efforts of the company,s ... technology. "Constance Dorian brings strong analytical skills ... regulations to,Biomoda. She will be an important asset ...
... announced it will host a webcast and conference call at 10 am,ET on ... which ended September 30. Financial results are,scheduled for release after the market closes ... and CEO, WHEN: Friday, November 2, 2007 ... Presentation: ...
... Group Urges Comprehensive Reform, End to Employer,Insurance ... care costs,threaten future U.S. economic growth. Today,s ... by an insurance system driven by,cost-conscious consumer ... Quality,Affordable Health Care for All: Moving Beyond ...
Cached Medicine News:Health News:NARSAD - the World's Leading Mental Health Research Charity - Presents 2007 Prizes for Outstanding Psychiatric Research at New York Gala, October 19th 2Health News:NARSAD - the World's Leading Mental Health Research Charity - Presents 2007 Prizes for Outstanding Psychiatric Research at New York Gala, October 19th 3Health News:Nicotine, Chili Peppers Offer Post-Surgery Pain Relief 2Health News:Nicotine, Chili Peppers Offer Post-Surgery Pain Relief 3Health News:DMP1 deletion cooperates with oncogenic K-ras in lung cancer 2Health News:Two Scientists Join Team of Biomoda, Inc. 2Health News:HMS Holdings Corp. Hosts Third Quarter 2007 Financial Teleconference and Presentation 2Health News:Quality, Affordable Health Care for All 2Health News:Quality, Affordable Health Care for All 3Health News:Quality, Affordable Health Care for All 4Health News:Quality, Affordable Health Care for All 5
... Recombinant immunofluorescent antibody ( RIFA:) ... semi-quantitation of human serum IgM ... antigen (VCA). Each kit contains ... recombinant EBV VCA antigen, FITC ...
When You Need Optimal Patient Comfort with Minimal Weight at a Nonunion Site...Demand The OrthoPak Noninvasive Bone Growth Stimulator., ,Most Appropriate for the Proximal Femur, Metatarsal/Tarsal...
... The StoneLight Laser System is a solid ... fragment stones in all areas of the ... tight spaces. , ,A variety of reusable ... with superior clinical versatility and outcomes. Standard ...
... CST-2000 Flexible Cystoscope System using EndoSheath ... solution for urologists in both their ... the CST-2000 flexible cystoscope with the ... between cystoscopy procedures, while minimizing the ...
Medicine Products: